Transaction in Own Shares | Financial Post


The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.



Source link

  • Related Posts

    Trade tensions, prices have Canadians cutting holiday shopping

    “Just like last year, we see further evidence of Canada-first sentiment in the low number of consumers planning to cross-border shop this holiday season,” the report said. Just over one out…

    Continue reading
    Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

    Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204,…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Business groups advocating for tax reforms to improve competitiveness

    Business groups advocating for tax reforms to improve competitiveness

    Trade tensions, prices have Canadians cutting holiday shopping

    The Verge’s guide to the best October Prime Day deals

    The Verge’s guide to the best October Prime Day deals

    Inside Ella Toone’s life on and off the pitch

    Inside Ella Toone’s life on and off the pitch

    British Airways Suspends 6 Major Routes From Heathrow: See List Now

    British Airways Suspends 6 Major Routes From Heathrow: See List Now

    Rockstar Says GTA 6 Won’t Be ‘Too Specific About Any Particular Person, Event, or Movement’

    Rockstar Says GTA 6 Won’t Be ‘Too Specific About Any Particular Person, Event, or Movement’